This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
This RCT compared daily 200mg or 300mg of FXI-ASO (an antisense oligonucleotide that reduces levels of factor XI) to daily 40mg of enoxaparin in pts undergoing knee replacement surgery. The end point was thromboembolism. FXI-ASO significantly reduced factor XI levels in a dose-response manner. FXI-ASO 200 mg was equivalent to enoxaparin in frequency of the end point (27% vs 30%) and FXI-ASO was superior (4%). Bleeding was evident in 8% after enoxaparin and in 4% after either dose of FXI-ASO.